BGM Group Ltd.(BGM)Earnings, Financials & Key Ratios
BGM•NASDAQ
$0.33
Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutBGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.Show more
- Revenue$25M-46.0%
- EBITDA$673K+145.9%
- Net Income-$1M+81.5%
- EPS (Diluted)-0.20+81.5%
- Gross Margin16.39%+335.0%
- EBITDA Margin2.68%+185.0%
- Operating Margin-2.25%+60.0%
- Net Margin-5.75%+65.7%
- ROE-3.26%+79.2%
BGM Price & Volume
BGM Group Ltd. (BGM) stock price & volume — 10-year historical chart
Loading chart...
Severe Revenue Contraction Threatens BGM Operational Viability
Investment Thesis • Updated N/A
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Deteriorating
Primary Risk:Severe Revenue Contraction Risk
Key Thesis Takeaways
- BGM Group Ltd.
- faces a precarious outlook characterized by a 45.99% year-over-year revenue decline and structural margin compression to 16.39%.
- The firm's disjointed product mix, spanning from pharmaceutical APIs to agricultural by-products, lacks the scale necessary to achieve profitability, as evidenced by a -2.25% operating margin.
- Investors should remain cautious as the company's $9.8 million cash reserve may be insufficient to navigate ongoing operational burn and potential asset impairments.
Verdict Logic
the company's inability to generate positive operating margins, combined with a 45.99% year-over-year revenue contraction, indicates significant fundamental distress.
BGM Growth Metrics
BGM Group Ltd. (BGM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-11.45%
3 Years-23.97%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years11.47%
5 Years4.16%
3 Years-0.92%
Last Year-1.27%
Peers Comparison
Key metrics vs top competitors for BGM Group Ltd. (BGM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.33 | $2.41M | -1.67 | -45.99% | -5.75% | -3.26% | — | |
| $1.31 | $180.01M | -27.87 | 44.01% | 5.15% | 19.13% | — | |
| $4.39 | $1.17B | -13.30 | 17.71% | -36.33% | -41.36% | — | |
| $15.56 | $10.44B | 31.76 | 53.03% | 35.55% | 22.55% | — | |
| $16.04 | $10.44B | 17.82 | 96.41% | 31.15% | 15.17% | — | |
| $8.02 | $2.37B | -18.65 | 115.25% | -3.48% | -3.75% | — |
Compare BGM vs Peers
BGM Group Ltd. (BGM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BGM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BGM Frequently Asked Questions
BGM Group Ltd. (BGM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BGM Group Ltd.'s revenue?
BGM Group Ltd. (BGM) reported $25.1M in revenue for fiscal year 2024. This represents a 11% increase from $22.5M in 2017.
How fast is BGM Group Ltd. growing?
BGM Group Ltd. (BGM) saw revenue decline by 46.0% over the past year.
Is BGM profitable?
BGM Group Ltd. (BGM) reported a net loss of $1.4M for fiscal year 2024.
Dividend & Returns
What is BGM's return on equity?
BGM Group Ltd. (BGM) has a return on equity (ROE) of -3.3%. Negative ROE indicates the company is unprofitable.
What is BGM Group Ltd.'s free cash flow?
BGM Group Ltd. (BGM) had negative free cash flow of $3.4M in fiscal year 2024, likely due to heavy capital investments.